Orion and Alligator reveal second stage of immuno-oncology research collaboration
Second study will develop a bispecific antibody with potential applications in solid tumours
Read More
Tag: orion
Nubeqa success in Phase III prostate cancer study
“A positive trend in overall survival” had been seen in a trial, with an interim analysis demonstrating a 29% reduction in the risk of death for Nubeqa.
Read More
Bayer, Orion win FDA priority review for darolutamide in prostate cancer
Darolutamide is an investigational, non-steroidal androgen receptor antagonist.
Read More
Darolutamide shows promise for treatment of prostate cancer
Orion’s and Bayer’s darolutamide has shown substantial efficacy in the treatment of prostate cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
